MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
350.63
-0.53
-0.15%
Pre Market: 352.20 +1.57 +0.45% 09:06 12/05 EST
OPEN
349.00
PREV CLOSE
351.16
HIGH
352.90
LOW
347.51
VOLUME
76
TURNOVER
0
52 WEEK HIGH
387.42
52 WEEK LOW
282.21
MARKET CAP
90.35B
P/E (TTM)
26.32
1D
5D
1M
3M
1Y
5Y
Better Growth Stock: CRISPR Therapeutics vs. Invitae
Growth stocks may be among the first to benefit in the next bull market. Gene-editing company crispr therapeutics and genetic-testing specialist invitae are key growth stocks to buy now. The former is heading for a big milestone, and the latter is on the road to recovery.
The Motley Fool · 9h ago
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Vertex pharmaceuticals's short percent of float has fallen 3.96% since its last report. The company has 2.51 million shares sold short, which is 0.97% of all regular shares. Short interest is the number of shares that have been sold short but not yet covered.
Benzinga · 1d ago
GSK vs. VRTX: Which Stock Should Value Investors Buy Now?
NASDAQ · 1d ago
Noteworthy ETF Outflows: QQQ, ADP, PDD, VRTX
NASDAQ · 1d ago
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Vertex pharmaceuticals (nasdaq:vrtx) has a return on equity of 21%. The average for its industry is 17% and the company has grown earnings growth of 16% over the last five years. Vertex's high roe suggests the company is reinvesting its profits to grow its business. It has a 21% rate of return on equity, compared to an industry average of 17%. The stock has been down 6.7% since the start of the year.
Simply Wall St · 1d ago
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Gene editing could unlock billions of dollars in latent value for investors. Crispr therapeutics and intellia are among the early leaders in the gene editing field. The field's uncertain future makes gene editing stocks worth owning as a hedge against the field's long-term prospects.
The Motley Fool · 1d ago
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA) and Vertex Pharmaceuticals (VRTX)
TipRanks · 1d ago
Hold Rating on Vertex Pharmaceuticals Pending Clinical Trial Outcomes
TipRanks · 1d ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Webull offers Vertex Pharmaceuticals Incorporated stock information, including NASDAQ: VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.